Strategies toward the Design of Novel and Selective Protein Tyrosine Kinase Inhibitors
- 1 May 1999
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 82 (2-3) , 195-206
- https://doi.org/10.1016/s0163-7258(98)00044-8
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Protein tyrosine kinase inhibitors in cancer treatmentExpert Opinion on Therapeutic Patents, 1997
- Crystal structure of the Src family tyrosine kinase HckNature, 1997
- Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivativesBioorganic & Medicinal Chemistry Letters, 1997
- Phenylamino-pyrimidine (PAP) — derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitorsBioorganic & Medicinal Chemistry Letters, 1996
- Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase InhibitorJournal of Biological Chemistry, 1996
- Editorial Oncologic, Endocrine & Metabolic: The current status of tyrosine kinase inhibitors: Do the diarylamine inhibitors of the EGF receptor represent a new beginning?Expert Opinion on Therapeutic Patents, 1995
- Patent Update: Oncologic, Endocrine & Metabolic Small molecule inhibitors of tyrosine kinase activityExpert Opinion on Therapeutic Patents, 1995
- Tyrosine Kinase Inhibition: An Approach to Drug DevelopmentScience, 1995
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994